Immunogenicity and Safety of Standard and <scp>Third‐Dose SARS</scp> – <scp>CoV</scp> ‐2 Vaccination in Patients Receiving Immunosuppressive Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunogenicity and Safety of Standard and Third‐Dose SARS – CoV ‐2 Vaccination in Patients Receiving Immunosuppressive Therapy

Published:2022-06-29 Issue:8 Volume:74 Page:1321-1332
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Syversen Silje W.¹^ORCID,Jyssum Ingrid²,Tveter Anne T.¹^ORCID,Tran Trung T.³,Sexton Joseph¹,Provan Sella A.¹^ORCID,Mjaaland Siri⁴,Warren David J.³,Kvien Tore K.²^ORCID,Grødeland Gunnveig⁵,Nissen‐Meyer Lise S. H.³,Ricanek Petr⁶,Chopra Adity³,Andersson Ane M.⁵^ORCID,Kro Grete B.³,Jahnsen Jørgen⁷,Munthe Ludvig A.⁵,Haavardsholm Espen A.²,Vaage John T.⁵,Lund‐Johansen Fridtjof⁵,Jørgensen Kristin K.⁶^ORCID,Goll Guro L.¹^ORCID

Affiliation:

1. Diakonhjemmet Hospital Oslo Norway

2. Diakonhjemmet Hospital and University of Oslo Oslo Norway

3. Oslo University Hospital Oslo Norway

4. Norwegian Institute of Public Health Oslo Norway

5. Oslo University Hospital and University of Oslo Oslo Norway

6. Akershus University Hospital Lørenskog Norway

7. University of Oslo, Oslo, and Akershus University Hospital Lørenskog Norway

Funder

Coalition for Epidemic Preparedness Innovations

Diakonhjemmet

Dr Trygve Gythfeldt og Frues Forskningsfond

Stiftelsen Kristian Gerhard Jebsen

Universitetet i Oslo

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.42153

Reference44 articles.

1. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

3. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

4. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

5. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study;eBioMedicine;2024-10

2. Actualización de las Guías para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología 2023;Reumatología Clínica;2024-05

3. Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023;Reumatología Clínica (English Edition);2024-05

4. A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection;Antimicrobial Agents and Chemotherapy;2024-04-03

5. The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA);Microbiology Spectrum;2024-04-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3